Description
PF-07263689 is an experimental medication currently being studied by Pfizer. It is being investigated as a potential treatment for certain advanced solid tumors, including colorectal cancer, specifically in patients who have already tried standard treatments. Clinical trials are evaluating its safety and effectiveness, both when given alone and in combination with another experimental drug called sasanlimab (which targets PD-1, a protein involved in the immune system's response to cancer). These trials are in the early phase (Phase 1), meaning they primarily focus on determining the right dose and assessing safety. The trials are looking at patients with microsatellite stable (MSS) tumors and considering PD-L1 expression levels.
Mechanism of Action
PF-07263689 is being studied to see how it affects viral load, shedding, pharmacodynamics, and anti-tumor activity. The specific way it works (its molecular target or mechanism of action) is still being investigated in these early clinical trials. It is being tested both by itself and in combination with sasanlimab, an anti-PD-1 antibody, suggesting it may interact with the immune system or have a mechanism that complements immunotherapy.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.